,

Investor Briefing with James McDonnell

October 20, 2025

Prescient Therapeutics: Investor Briefing with CEO James McDonnell

CEO James McDonnell, held a shareholder briefing with Reach Markets.

In this session, James discussed:

  • Progress of the Phase 2a study for cancer treatment PTX-100 with 7 clinical trials sites open in Australia and the United States.
  • The sub-analysis of CTCL in Phase 1b with patients exhibiting a 100% clinical benefit rate and no serious adverse events.
  • Their First-in-class technology which could apply to 22% of all cancer cases.

Recorded on 20th October 2025 at 11am (AEDT)

Join the next Prescient Therapeutics webcast

Register to stay up to date with Prescient Therapeutics

Featured Speaker

James McDonnell

CEO

James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.

Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company’s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.

James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.

Related Post

This investor centre was built by Reach Markets

©2026 Reach Markets

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.
  • A gross income of $250,000 or more per annum in each of the previous two financial years; or
  • Net assets of at least $2.5 million; and
  • A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
×

Any advice is general only

Any advice provided by Reach Markets, the Lead Manager on this offer, including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice.

×

Receive email updates

What is a 708 investor?

By submitting this form, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.